Retension Pharmaceuticals, Inc. (NASDAQ:RTSN)
| Market Cap | 57.19M+44.8% |
| Revenue (ttm) | n/a |
| Net Income | n/a |
| EPS | n/a |
| Shares Out | 3.75M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 77,405 |
| Open | 15.85 |
| Previous Close | 15.50 |
| Day's Range | 14.43 - 16.29 |
| 52-Week Range | 9.66 - 18.64 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
Retension Pharmaceuticals, Inc. has a live Insider Score.
Scored on 2 qualifying trades from 2 insiders in the last 90 days.
About RTSN
Retension Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Its product, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. The company was founded by Eric Keller and Paul Sweetnam in 2023 and is headquartered in Falls Church, VA.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Latest News
InsiderBuyingOur analysisTwo Retension Pharmaceuticals Insiders Buy $369,600 of StockFranklin M Berger and Eric L. Keller are both recorded as buyers at Retension Pharmaceuticals, with purchases dated October 13th, 2026 totaling $369,600. The shares last traded at $15.Oct 22, 2026InsiderBuyingOur analysisTwo Retension Pharmaceuticals Insiders Buy $369,600 of StockFranklin M Berger and Eric L. Keller are the two insiders on the buy side at Retension Pharmaceuticals, with $369,600 in purchases recorded on October 13th, 2026. Shares were last marked at $11.63.Oct 14, 2026$RTSN stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in RTSN holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by RTSN's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
RTSN Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New RTSN patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to RTSN from public contracts
Source: USAspending.gov
RTSN Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from RTSN’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score